R
R. B. Raney
Researcher at University of Texas MD Anderson Cancer Center
Publications - 16
Citations - 1144
R. B. Raney is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Rhabdomyosarcoma & Sarcoma. The author has an hindex of 10, co-authored 16 publications receiving 1084 citations.
Papers
More filters
Journal ArticleDOI
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
R. B. Raney,James G. Anderson,Frederic G. Barr,Sarah S. Donaldson,Alberto S. Pappo,Stephen J. Qualman,Eugene S. Wiener,Harold M. Maurer,William M. Crist +8 more
TL;DR: The IRS-V protocols are risk-based and refine therapy by reducing exposure to cyclophosphamide and radiation therapy (XRT) in patients at low risk while adding new, active agents such as topotecan or irinotecans to the standard therapy for patients with unfavorable histology or advanced disease.
Journal ArticleDOI
Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991.
R. B. Raney,Lina Asmar,William A. Newton,C Bagwell,John C. Breneman,William M. Crist,E. Gehan,Bruce Webber,Moody D. Wharam,Eugene S. Wiener,James R. Anderson,Harold M. Maurer +11 more
TL;DR: This series indicated that EOE in children is similar to rhabdomyosarcoma (RMS) in its response to multimodal treatment.
Journal ArticleDOI
Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee.
Ruth M. Heyn,Veronica Haeberlen,William A. Newton,A. H. Ragab,R. B. Raney,M. Tefft,Moody D. Wharam,L G Ensign,Harold M. Maurer +8 more
TL;DR: The results of this study suggest that genetic abnormalities play a prominent role in the development of an SMN after therapy for a primary RMS and Chemotherapy with an alkylating agent and radiotherapy play significant roles in theDevelopment of anSMN compared with patients who received only one of these therapeutic modalities.
Journal ArticleDOI
Treatment of children and adolescents with localized parameningeal sarcoma: Experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS‐II through ‐IV, 1978–1997*†
R. B. Raney,Jane L. Meza,James R. Anderson,Chris Fryer,Sarah S. Donaldson,John C. Breneman,Thomas J. Fitzgerald,Edmund A. Gehan,Jeff M. Michalski,Jorge A. Ortega,Stephen J. Qualman,Eric Sandler,Moody D. Wharam,Eugene S. Wiener,Harold M. Maurer,William M. Crist +15 more
TL;DR: Biopsy, XRT to the target volume, and systemic chemotherapy are successful treatments for the large majority of patients with localized parameningeal sarcoma and aggressive initial surgical management of these patients is unnecessary.
Journal ArticleDOI
Late effects of therapy in patients with paratesticular rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee.
TL;DR: The findings suggest that some aspects of therapy warrant reevaluation and that improved plans for follow-up care need to be provided.